Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.

PLoS One · 2016 · PMC4858302 · PMID 27149269

Europe PMC DOI

hedged sentences

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significancep = 0.09so close (0.05 < p ≤ 0.1)

Furthermore, although the pooled RRs did not reach statistical significance, a trend towards a higher incidence of headache was observed in the QS-21-adjuvanted vaccine group (pooled RR 1.66, 95% CI 0.93–2.97, p = 0.09).

also in 111,027 other papers

showed a trendno p-value reported

Furthermore, the results showed a trend towards an increased risk for injection site redness/erythema in patients receiving saponin-adjuvanted vaccine compared to those receiving placebo, although it was not statistically significant (pooled RR 1.44, 95% CI 0.95–2.17, p = 0.08).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.